Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations and Comprehensive Loss

v3.19.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Revenues $ 260,000 $ 260,000
Operating expenses:    
Research and development costs 3,960,191 8,096,095
General and administrative expenses 4,559,265 5,471,010
Total operating expenses 8,519,456 13,567,105
Operating loss (8,259,456) (13,307,105)
Other income (expense):    
Interest income 78,780 70,269
Interest expense (7,698) (159,066)
Gain (loss) from change in fair value of liability classified warrants 3,269,148 (1,470,174)
Fees related to issuance of liability classified warrants and other expenses (5,391) (799,907)
Total other income (expense) 3,334,839 (2,358,878)
Net loss $ (4,924,617) $ (15,665,983)
Net loss per common share - basic and diluted (in dollars per share) $ (0.32) $ (1.20)
Weighted average common shares outstanding - basic and diluted (in shares) 15,156,925 13,064,422
Comprehensive loss:    
Net loss $ (4,924,617) $ (15,665,983)
Foreign currency translation adjustment (3,044) (1,274)
Comprehensive loss $ (4,927,661) $ (15,667,257)